Key points
- Atezolizumab (Tecentriq) is an immunotherapy drug: it releases the brake the cancer has put on the immune system so the body can fight the cancer [1].
- It is used for lung cancer, liver cancer (with bevacizumab), melanoma, bladder cancer and colon cancer [1].
- It is given as a drip every 2, 3 or 4 weeks; the first infusion takes 60 minutes and later ones often 30 minutes [1].
- The most common side effects: tiredness (in about half of patients), poor appetite, nausea, cough and shortness of breath [1].
- The main risk is immune-related inflammation of the lungs, bowel, liver, glands, kidneys or skin, which can appear even after treatment ends; report any new symptom early [1] (immunotherapy side effects).
- Women should use reliable contraception during treatment and for 5 months after the last dose, and should not breastfeed [1].
What is this drug and how does it work?
For physicians
Atezolizumab (brand name Tecentriq) is a humanised IgG1 monoclonal antibody from the group of immunotherapy drugs called immune checkpoint inhibitors [1]. It works differently from chemotherapy: instead of damaging cells directly, it removes the inhibition the tumour places on the immune system [1].
Some cancer cells and tumour-infiltrating immune cells carry a protein called PD-L1. Binding of PD-L1 to the PD-1 and B7.1 receptors on T cells and antigen-presenting cells suppresses T-cell cytotoxic activity, proliferation and cytokine production. Atezolizumab binds PD-L1 and blocks its interaction with both receptors, releasing the inhibition of the immune response and activating the antitumour immune response [1].
This immune activation is also the main reason for the drug's particular side effects: the immune system sometimes attacks healthy tissues and organs too [1].
Which cancers is it used for?
The indications in the table below are based on the current US FDA label [1]. Some uses need a biomarker test: PD-L1 expression in lung cancer, BRAF V600 mutation in melanoma, ctDNA in bladder cancer and dMMR status in colon cancer [1]. Approvals may differ between countries, and not every patient with these cancers is a candidate for this drug; the final decision rests with the treatment team.
Your doctor may prescribe this drug for:
- Non-small cell lung cancer, as treatment after surgery [1, 2]
- Non-small cell lung cancer that has spread, first line, on its own [1]
- Non-squamous non-small cell lung cancer that has spread, first line, in combination [1, 3]
- Non-small cell lung cancer that has spread, after chemotherapy [1]
- Extensive-stage small cell lung cancer [1, 4]
- Hepatocellular carcinoma [1, 5]
- Melanoma [1]
- Alveolar soft part sarcoma (ASPS) [1]
- Muscle-invasive bladder cancer [1, 6]
- Stage III colon cancer with dMMR [1, 7]
- Cervical cancer (not an FDA-labelled use) [1, 8]
Whether it suits you depends on the type and stage of your cancer and your test results. Details of each use are in the section for doctors.
For physicians
| Cancer | Conditions of use | Key evidence |
|---|---|---|
| Non-small cell lung cancer — adjuvant | Monotherapy after surgery and platinum-based chemotherapy in stage II to IIIA with PD-L1 on 1% or more of tumour cells; up to one year [1] | IMpower010 trial: hazard ratio for recurrence or death 0.66 in stage II to IIIA with PD-L1 1% or more [1, 2] |
| Metastatic non-small cell lung cancer — first line, monotherapy | High PD-L1 expression (TC 50% or more or IC 10% or more) and no EGFR or ALK alteration [1] | IMpower110 trial: median overall survival 20.2 vs 13.1 months compared with platinum-based chemotherapy [1] |
| Metastatic non-squamous non-small cell lung cancer — first line, combination | With bevacizumab, paclitaxel and carboplatin, or with protein-bound paclitaxel and carboplatin; no EGFR or ALK alteration [1] | IMpower150 trial: median overall survival 19.2 vs 14.7 months (four-drug regimen vs bevacizumab and chemotherapy); IMpower130 trial [1, 3] |
| Metastatic non-small cell lung cancer — after chemotherapy | Monotherapy after progression during or after platinum-based chemotherapy (with EGFR or ALK alterations, after the relevant targeted therapy) [1] | OAK trial: median overall survival 13.8 vs 9.6 months compared with docetaxel [1] |
| Extensive-stage small cell lung cancer | First line with carboplatin and etoposide; maintenance with lurbinectedin in patients without progression after induction [1] | IMpower133 trial: median overall survival 12.3 vs 10.3 months; IMforte trial for maintenance [1, 4] |
| Hepatocellular carcinoma | With bevacizumab in unresectable or metastatic disease without prior systemic therapy [1] | IMbrave150 trial: hazard ratio for death 0.58 and median progression-free survival 6.8 vs 4.3 months compared with sorafenib [1, 5] |
| Melanoma | With cobimetinib and vemurafenib in unresectable or metastatic BRAF V600-mutant melanoma [1] | IMspire150 trial [1] |
| Alveolar soft part sarcoma (ASPS) | Monotherapy in adults and children aged 2 years and over with unresectable or metastatic disease [1] | FDA label [1] |
| Muscle-invasive bladder cancer | Adjuvant monotherapy after cystectomy in patients who are ctDNA-positive (molecular residual disease) [1] | IMvigor011 trial: median disease-free survival 9.9 vs 4.8 months and median overall survival 32.8 vs 21.1 months compared with placebo [1, 6] |
| Stage III colon cancer with dMMR | Adjuvant with a fluoropyrimidine and oxaliplatin, then as monotherapy; adults and children aged 2 years and over [1] | ATOMIC trial: hazard ratio for recurrence or death 0.50 compared with mFOLFOX6 alone [1, 7] |
| Cervical cancer (not an FDA-labelled use) | With bevacizumab and chemotherapy in metastatic, persistent or recurrent disease; this use is not among the FDA label indications [1] | BEATcc trial: median progression-free survival 13.7 vs 10.4 months [8] |
The table is based on the FDA label (revised October 2026). The last row is not an FDA-labelled use.
How it is taken and dosing
Show detailsHide
Treatment regimens and doses: index8 regimens
Atezolizumab is given in a hospital or treatment centre as an intravenous infusion (drip). The first infusion takes 60 minutes and, if it is well tolerated, later infusions can be given over 30 minutes [1]. Depending on the regimen, it is repeated every 2, 3 or 4 weeks [1].
How long treatment lasts depends on the cancer: in metastatic disease it continues until the disease progresses or a side effect cannot be tolerated, and as adjuvant treatment after lung or bladder surgery it lasts up to one year [1]. In colon cancer it is given for 6 months with chemotherapy and then for 6 months on its own [1].
Before starting and regularly during treatment, blood tests check liver enzymes, creatinine (kidney function) and thyroid function [1]. If you miss an infusion appointment, contact your treatment team as soon as possible to rearrange it [1].
- Patient selection: confirm PD-L1 (adjuvant NSCLC and first-line monotherapy), BRAF V600 mutation (melanoma), ctDNA MRD in serial samples between 6 weeks and 1 year after cystectomy (bladder) and dMMR status (colon) before starting [1].
- Administration: diluted in 0.9% sodium chloride (3.2 to 16.8 mg/mL); never as an IV push or bolus [1].
- Before starting and periodically: liver enzymes, creatinine and thyroid function; monitor blood glucose and symptoms of immune-related adverse events [1].
- General principle: no dose reductions are recommended. Grade 3 immune-related adverse event: withhold; grade 4, recurrent grade 3 requiring immunosuppression, or inability to taper prednisone to ≤10 mg/day within 12 weeks: discontinue permanently. Corticosteroids 1 to 2 mg/kg/day until grade ≤1, then taper over at least 1 month [1].
- Pneumonitis: grade 2 withhold; grade 3 to 4 discontinue permanently. Colitis: grade 2 to 3 withhold; grade 4 discontinue permanently [1].
- Hepatitis without liver involvement: AST/ALT above 3 to 8 times or bilirubin above 1.5 to 3 times: withhold; AST/ALT above 8 times or bilirubin above 3 times: discontinue permanently. With liver involvement (e.g., HCC): baseline above 1 to 3 times rising to above 5 to 10 times, or baseline above 3 to 5 times rising to above 8 to 10 times: withhold; above 10 times or bilirubin above 3 times: discontinue permanently [1].
- Other: nephritis with grade 2 to 3 creatinine withhold, grade 4 discontinue permanently; grade 3 to 4 endocrinopathy withhold until stable or discontinue; grade 2 to 4 myocarditis/pericarditis discontinue permanently; grade 2 neurological toxicity withhold, grade 3 to 4 discontinue permanently; suspected SJS/TEN/DRESS withhold, confirmed discontinue permanently [1].
- Infusion reaction: grade 1 to 2: interrupt or slow the infusion and consider premedication for later doses; grade 3 to 4: discontinue permanently [1].
- Kidney and liver: mild and moderate renal impairment (eGFR 30 to 89) and mild and moderate hepatic impairment have no clinically meaningful effect on exposure [1].
For physicians
Standard dosing: monotherapy (FDA label)
Atezolizumab monotherapy
Metastatic NSCLC (first line with high PD-L1: TC ≥50% or IC ≥10% without EGFR/ALK; or after platinum chemotherapy); ASPS in adults
Metastatic NSCLC (first line with high PD-L1: TC ≥50% or IC ≥10% without EGFR/ALK; or after platinum chemotherapy); ASPS in adults
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV (60 minutes; later ones 30 minutes) | Day 1 |
Adjuvant atezolizumab
Stage II to IIIA NSCLC after resection and platinum-based chemotherapy with PD-L1 ≥1% of tumour cells; muscle-invasive bladder cancer after cystectomy with positive ctDNA MRD (FDA-approved test)
Stage II to IIIA NSCLC after resection and platinum-based chemotherapy with PD-L1 ≥1% of tumour cells; muscle-invasive bladder cancer after cystectomy with positive ctDNA MRD (FDA-approved test)
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV (60 minutes; later ones 30 minutes) | Day 1 |
Atezolizumab in children (ASPS)
Unresectable or metastatic alveolar soft part sarcoma, age ≥2 yearsCycle length: Every 3 weeks
Unresectable or metastatic alveolar soft part sarcoma, age ≥2 years
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Atezolizumab | 15 mg/kg (maximum 1200 mg) | IV | Day 1 |
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Combination regimens (FDA label)
Atezolizumab + carboplatin + etoposide (IMpower133)
Extensive-stage small cell lung cancer, first line
Extensive-stage small cell lung cancer, first line
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Induction: up to 4 cycles | |||
| Atezolizumab | 1200 mg | IV, before chemotherapy | Day 1 |
| Induction | |||
| Carboplatin | AUC 5 mg/mL×min | IV | Day 1 |
| Etoposide | 100 mg/m² | IV | Days 1 to 3 |
| Maintenance | |||
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV | |
Chemotherapy doses are those of the IMpower133 trial in the label [1]. For maintenance without progression after induction, atezolizumab 1200 mg with lurbinectedin 3.2 mg/m² IV every 3 weeks (IMforte trial) is also approved; in IMforte, 84% of patients received prophylactic G-CSF [1].
Evidence: IMpower133 (2018)
Atezolizumab + bevacizumab + paclitaxel + carboplatin (IMpower150)
Metastatic non-squamous NSCLC without EGFR/ALK, first lineCycle length: Every 21 days
Metastatic non-squamous NSCLC without EGFR/ALK, first line
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Induction: 4 or 6 cycles | |||
| Atezolizumab | 1200 mg | IV, first of all | Day 1 |
| Induction | |||
| Bevacizumab | 15 mg/kg | IV | Day 1 |
| Paclitaxel | 175 or 200 mg/m² | IV | Day 1 |
| Carboplatin | AUC 6 | IV | Day 1 |
| Maintenance | |||
| Atezolizumab + bevacizumab | 1200 mg + 15 mg/kg | IV | Day 1 |
Alternative regimen (IMpower130): atezolizumab 1200 mg and carboplatin AUC 6 on day 1 and protein-bound paclitaxel 100 mg/m² on days 1, 8 and 15 every 21 days, for 4 or 6 cycles; then atezolizumab every 3 weeks [1].
Evidence: IMpower150 (2018)
Atezolizumab + bevacizumab (IMbrave150)
Unresectable or metastatic hepatocellular carcinoma without prior systemic therapy
Unresectable or metastatic hepatocellular carcinoma without prior systemic therapy
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV, before bevacizumab | Day 1 |
| Bevacizumab | 15 mg/kg | IV | Every 3 weeks |
In IMbrave150, patients were assessed for varices within 6 months before treatment, and untreated or incompletely treated varices with bleeding or at high risk of bleeding were an exclusion criterion; variceal bleeding was the most common cause of death from an adverse event (1.2%) [1].
Evidence: IMbrave150 (2022), IMbrave150 (2020)
Atezolizumab + cobimetinib + vemurafenib
Unresectable or metastatic melanoma with a BRAF V600 mutationEach drug’s schedule in the table
Unresectable or metastatic melanoma with a BRAF V600 mutation
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| First 28-day cycle (no atezolizumab) | |||
| Cobimetinib | 60 mg once daily | Oral | Days 1 to 21, then 7 days off |
| First cycle | |||
| Vemurafenib | 960 mg twice daily (days 1 to 21), then 720 mg twice daily (days 22 to 28) | Oral | Every day, days 1 to 28 |
| From cycle 2 | |||
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV | Every 2, 3 or 4 weeks (depending on the dose) |
| Cobimetinib | 60 mg once daily | Oral | 21 days on, 7 days off |
| Vemurafenib | 720 mg twice daily | Oral | Every day |
Atezolizumab + mFOLFOX6 (ATOMIC)
Stage III colon cancer with dMMR, adjuvant (adults and children ≥2 years)
Stage III colon cancer with dMMR, adjuvant (adults and children ≥2 years)
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| First 6 months | |||
| Atezolizumab | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks; children: 10 mg/kg (maximum 840) every 2 weeks or 15 mg/kg (maximum 1200) every 3 weeks | IV, before chemotherapy | |
| mFOLFOX6 (oxaliplatin, leucovorin, fluorouracil) | As per the drug labels | IV | Every 14 days, 12 cycles |
| Second 6 months | |||
| Atezolizumab monotherapy | 840 mg every 2 weeks, or 1200 mg every 3 weeks, or 1680 mg every 4 weeks | IV | |
Before prescribing, check each dose against the drug label, laboratory tests and the patient’s condition.
Side effects
The most common side effects:
- Tiredness and weakness (in about half of patients), poor appetite, nausea, cough and shortness of breath [1].
- When it is given with chemotherapy, hair loss, constipation and diarrhoea are also common [1].
- Tell your treatment team early about any new or worsening symptom; it may be the first sign of an immune side effect, and early treatment stops it from becoming severe [1].
For physicians
Common adverse reactions differ depending on whether the drug is given alone or with other drugs. Frequencies from the FDA label [1]:
- Monotherapy (2616 patients in clinical trials): fatigue/asthenia 48%, decreased appetite 25%, nausea 24%, cough 22% and dyspnoea 22% [1].
- With chemotherapy in lung cancer (2421 patients): fatigue/asthenia 49%, nausea 38%, alopecia 35%, constipation 29%, diarrhoea 28% and decreased appetite 27% [1].
- With bevacizumab in hepatocellular carcinoma (IMbrave150 trial, 329 patients): hypertension 30%, fatigue/asthenia 26% and proteinuria 20% [1].
- With mFOLFOX6 in colon cancer (ATOMIC trial, 346 patients): nausea 75%, diarrhoea 73%, peripheral sensory neuropathy 62%, decreased appetite 48%, abdominal pain 47% and constipation 43% [1].
- Adjuvant treatment of bladder cancer (IMvigor011 trial, 165 patients): urinary tract infection 22% (vs 18% with placebo), pruritus 18%, rash 13% and hypothyroidism 13% [1].
Patients should report any new or worsening symptom to the treatment team, as it may be the first sign of an immune-related adverse event, and early treatment prevents it from becoming more severe [1].
Serious side effects
Immunotherapy sometimes makes the immune system attack healthy organs too. These side effects can happen at any time, even after treatment has ended [1] (immunotherapy side effects):
- Lungs: a new cough, shortness of breath or chest pain [1].
- Bowel: diarrhoea, abdominal pain or blood in the stool [1].
- Liver: yellow skin or eyes, dark urine [1].
- Glands: severe tiredness, weight change, severe headache, thirst and passing a lot of urine (sudden diabetes) [1].
- Skin, kidneys, heart and nerves: rash or blisters, passing less urine, palpitations, muscle weakness [1].
- A reaction during the infusion (chills, fever, shortness of breath) and harm to an unborn baby [1].
For physicians
Atezolizumab has no boxed warning, but the FDA label emphasises severe and sometimes fatal immune-related adverse reactions. They can occur in any organ, at any time after starting treatment and even after the drug is stopped [1]. The frequencies below are for 2616 patients receiving monotherapy [1]:
- Pneumonitis: 3%; more common in patients who have had chest radiotherapy [1].
- Hypothyroidism: 4.9% (17% in adjuvant lung cancer treatment in IMpower010); hyperthyroidism: 0.8% [1].
- Immune-mediated hepatitis: 1.8% [1].
- Colitis: 1% [1].
- Adrenal insufficiency: 0.4%; type 1 diabetes (sometimes with diabetic ketoacidosis): 0.3%; hypophysitis: below 0.1% [1].
- Immune-mediated skin reactions: 0.6%; severe skin reactions such as SJS, TEN and DRESS have been reported with drugs of this class [1].
- Nephritis with renal dysfunction: below 0.1% [1].
- Other immune-related adverse reactions (mostly below 1%): myocarditis, pericarditis, meningitis, encephalitis, myasthenia gravis, Guillain-Barré syndrome, uveitis, pancreatitis, myositis and solid organ transplant rejection [1].
- Infusion-related reactions: 1.3% (grade 3: 0.2%); severe reactions including anaphylaxis can occur [1].
- Allogeneic stem cell transplantation: serious and sometimes fatal complications (such as graft-versus-host disease) have been reported in patients receiving an allogeneic transplant before or after these drugs [1].
- Embryo-fetal toxicity: based on its mechanism of action, the drug can harm a fetus [1].
With bevacizumab in hepatocellular carcinoma, serious adverse reactions occurred in 38% of patients, most often gastrointestinal haemorrhage (7%); fatal adverse reactions were reported in 4.6% [1].
When should I call my doctor?
Contact your treatment team straight away if you have any of these new or worsening symptoms [1]:
- A new or worsening cough, chest pain or shortness of breath
- Diarrhoea or more frequent bowel movements, black tarry stools or stools with blood or mucus, severe abdominal pain or tenderness
- Yellow skin or whites of the eyes, severe nausea or vomiting, pain on the right side of the abdomen, dark (tea-coloured) urine, bleeding or bruising easily
- A persistent or unusual headache, eye sensitivity to light, palpitations, extreme tiredness, unusual thirst or hunger, passing urine more often, dizziness or fainting
- Passing less urine, blood in the urine, swollen ankles
- Rash, itching, blistering or peeling skin, painful sores in the mouth, nose, throat or genital area
- An irregular heartbeat, confusion, sleepiness, a stiff neck, double or blurred vision, severe muscle pain or weakness
- During or after an infusion: chills, itching, flushing, wheezing or shortness of breath, dizziness, fever, back or neck pain
In severe cases (such as severe shortness of breath, chest pain or reduced consciousness), call your local emergency number.
Interactions, pregnancy and precautions
Drug interactions: the FDA label for atezolizumab has no section on drug interactions [1]; even so, tell your doctor the full list of your prescription and over-the-counter medicines, vitamins and herbal supplements [1].
Tell your doctor before starting if you have: an autoimmune disease (such as Crohn disease, ulcerative colitis or lupus), had an organ or corneal transplant, had or plan an allogeneic stem cell transplant, had chest radiotherapy, or have a nerve disease such as myasthenia gravis or Guillain-Barré syndrome [1].
Pregnancy and contraception: pregnancy status is checked before treatment. Women who could become pregnant should use effective contraception during treatment and for at least 5 months after the last dose, and tell their doctor straight away if they become pregnant or think they might be [1].
Breastfeeding: do not breastfeed during treatment and for at least 5 months after the last dose [1].
Fertility: based on animal studies, atezolizumab may reduce female fertility during treatment [1].
Vaccines: the FDA label gives no specific advice about vaccination during treatment [1]; talk to your treatment team before any vaccine.
Older adults: overall, no difference in safety or effectiveness was seen between patients aged 65 and over and younger patients; however, with chemotherapy in colon cancer, severe adverse reactions were slightly more common in people aged 65 and over [1].
Frequently asked questions
Is atezolizumab chemotherapy?
No. Atezolizumab is an immunotherapy antibody that removes the brake on the immune system by blocking PD-L1 [1]. In some cancers, though, it is given with chemotherapy, for example with carboplatin and etoposide in extensive-stage small cell lung cancer [1].
Does this drug make your hair fall out?
How long does each session take, and how long does treatment go on?
The first infusion takes 60 minutes and, if tolerated, later infusions take 30 minutes; they are repeated every 2, 3 or 4 weeks [1]. In metastatic disease, treatment continues until the disease progresses or a side effect cannot be tolerated; as adjuvant treatment (lung, bladder, colon) it lasts up to about one year [1].
Can side effects appear after treatment has ended?
Yes. Immune-related side effects usually appear during treatment, but they can also appear after the drug is stopped [1]. So if you notice a new symptom after treatment has ended, tell your doctor that you have had atezolizumab.
Which tests are needed before receiving this drug?
It depends on the cancer: a PD-L1 test in non-small cell lung cancer, BRAF V600 mutation in melanoma, ctDNA after cystectomy in bladder cancer and dMMR status in colon cancer [1]. According to the label, there is currently no FDA-approved test for dMMR in colon cancer [1]. Liver, kidney and thyroid tests are also repeated during treatment [1].
Scientific evidence
Show detailsHide
Key studies
5 itemsAtezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Related cancer types
Treatment regimens (physicians)
References
8 referencesShow all references, 7 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1TECENTRIQ (atezolizumab) injection, for intravenous use: Prescribing InformationSource Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113
- 2Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- 3Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- 4First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- 5Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- 6ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- 7Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
- 8Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/drugs/atezolizumab/